ArticlePLoS neglected tropical diseases2014
Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.
Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate.Journal of virology · 2026Article
- Comparative molecular, innate, and adaptive impacts of chemically diverse STING agonists.Vaccine · 2025Review
- A single dose recombinant AAV based CHIKV vaccine elicits robust and durable protective antibody responses in mice.PLoS neglected tropical diseases · 2024Article
- Chikungunya fever.Nature reviews. Disease primers · 2023Review
- Chikungunya Virus: Priority Pathogen or Passing Trend?Vaccines · 2023Review
- Article
- Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to theExperimental and therapeutic medicine · 2023Review
- Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice.Frontiers in immunology · 2023Article
- A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection.Frontiers in immunology · 2023Article
- Generation of a Live-Attenuated Strain of Chikungunya Virus from an Indian Isolate for Vaccine Development.Vaccines · 2022Article
- An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.Virologica Sinica · 2022Article
- Chikungunya Virus Vaccines: Platforms, Progress, and Challenges.Current topics in microbiology and immunology · 2022Review
- Chikungunya Vaccine Candidates: Current Landscape and Future Prospects.Drug design, development and therapy · 2022Review
- Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus.Biomedicines · 2021Review
- Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.Microorganisms · 2021Review
- Multi-laboratory evaluation of ReaScan TBE IgM rapid test, 2016 to 2017.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Observational
- Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections.Frontiers in immunology · 2020Review
- Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.Journal of virology · 2019Article
- 51 years in of Chikungunya clinical vaccine development: A historical perspective.Human vaccines & immunotherapeutics · 2019Review
- A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control.Acta tropica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) infection is characterized by rash, acute high fever, chills, headache, nausea, photophobia, vomiting, and severe polyarthralgia. There is evidence that arthralgia can persist for years and result in long-term discomfort. Neurologic disease with fatal outcome has been documented, although at low incidences. The CHIKV RNA genome encodes five structural proteins (C, E1, E2, E3 and 6K). The E1 spike protein drives the fusion process within the cytoplasm, while the E2 protein is believed to interact with cellular receptors and therefore most probably constitutes the target of neutralizing antibodies. We have constructed recombinant Modified Vaccinia Ankara (MVA) expressing E3E2, 6KE1, or the entire CHIKV envelope polyprotein cassette E3E26KE1. MVA is an appropriate platform because of its demonstrated clinical safety and its suitability for expression of various heterologous proteins. After completing the immunization scheme, animals were challenged with CHIV-S27. Immunization of AG129 mice with MVAs expressing E2 or E3E26KE1 elicited neutralizing antibodies in all animals and provided 100% protection against lethal disease. In contrast, 75% of the animals immunized with 6KE1 were protected against lethal infection. In conclusion, MVA expressing the glycoprotein E2 of CHIKV represents as an immunogenic and effective candidate vaccine against CHIKV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.